Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using OKT3 to reverse cardiac allograft rejection.

K R Rogers1, J T Sinnott, J E Ferguson

  • 1Cardiac Transplant Services, Tampa General Hospital, FL 33601.

Heart & Lung : the Journal of Critical Care
|September 1, 1989
PubMed
Summary

OKT3 effectively reversed acute rejection in cardiac transplant patients, offering a safer alternative to traditional treatments. This new approach minimized side effects, improving patient survival and recovery outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender differences in PTSD severity and pain outcomes: baseline results from the LAMP trial.

medRxiv : the preprint server for health sciences·2023
Same author

It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis.

Urologic oncology·2017
Same author

The changing practice of the obstetrician.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Cucurbitacins : Plant-derived defense compounds for diabroticites (Coleoptera: Chrysomelidae).

Journal of chemical ecology·2013
Same author

Disposition and fate of cucurbitacin B in five species of diabroticites.

Journal of chemical ecology·2013
Same author

Favre-Racouchot syndrome: a novel two-step treatment approach using the carbon dioxide laser.

The British journal of dermatology·2013

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Acute rejection remains a primary obstacle to long-term survival following organ transplantation.
  • Current treatments for cardiac allograft rejection, such as cytotoxic agents and high-dose steroids, are associated with significant adverse effects.
  • Novel therapeutic strategies are needed to manage acute rejection episodes more effectively and with reduced morbidity.

Purpose of the Study:

  • To evaluate the efficacy and safety of OKT3 in reversing acute rejection episodes in cardiac transplant recipients.
  • To assess the side effect profile of OKT3 therapy in this patient population.
  • To develop a nursing care plan for managing OKT3 therapy, including patient education and adverse event recognition.

Main Methods:

Related Experiment Videos

  • A cohort of 10 cardiac transplant recipients experiencing acute rejection was treated with OKT3.
  • Clinical outcomes, including the reversal of rejection and resolution of symptoms, were monitored.
  • Adverse events and side effects associated with OKT3 administration were systematically recorded.

    • Main Results:

    • OKT3 demonstrated dramatic reversal of acute rejection episodes in all 10 patients.
    • Clinical symptoms associated with rejection were resolved following OKT3 treatment.
    • Reported side effects were minimal, including fever, mild diarrhea, opportunistic infections, and one instance of hypotension.

    Conclusions:

    • OKT3 is a promising agent for reversing acute cardiac allograft rejection with a favorable safety profile.
    • The findings support the use of OKT3 as a less morbid alternative to conventional immunosuppressive therapies.
    • A comprehensive nursing care plan is essential for optimizing OKT3 therapy and managing potential adverse effects in transplant patients.